Transcatheter aortic valve replacement (TAVR) is a treatment option for symptomatic patients with severe
aortic stenosis who are candidates for a
bioprosthesis across the entire spectrum of risk. However, TAVR carries a risk for thrombotic and
bleeding events, underscoring the importance of defining the optimal adjuvant antithrombotic regimen. Antithrombotic considerations are convoluted by the fact that many patients undergoing TAVR are generally elderly and present with multiple comorbidities, including conditions that may require long-term oral anticoagulation (OAC) (eg,
atrial fibrillation) and antiplatelet
therapy (eg,
coronary artery disease). After TAVR among patients without baseline indications for OAC, recent data suggest dual-antiplatelet
therapy to be associated with an increased risk for
bleeding events, particularly early postprocedure, compared with single-antiplatelet
therapy with
aspirin. Concerns surrounding the potential for thrombotic complications have raised the hypothesis of adjunctive use of OAC for patients with no baseline indications for anticoagulation. Although effective in modulating
thrombus formation at the valve level, the
bleeding hazard has shown to be unacceptably high, and the net benefit of combining antiplatelet and OAC
therapy is unproven. For patients with indications for the use of long-term OAC, such as those with
atrial fibrillation, the adjunctive use of antiplatelet
therapy increases
bleeding. Whether direct oral
anticoagulant agents achieve better outcomes than
vitamin K antagonists remains under investigation. Overall, single-antiplatelet
therapy and OAC appear to be reasonable strategies in patients without and with indications for concurrent anticoagulation. The aim of the present review is to appraise the current published research and recommendations surrounding the management of antithrombotic
therapy after TAVR, with perspectives on evolving paradigms and ongoing trials.